Peptides

What peptide therapy actually costs in 2026 — and what a prescriber may lawfully offer

By the US Health Digest editorial team · August 4, 2026

In August 2026, the price of "peptide therapy" in the United States depends almost entirely on which of three markets you are buying in: an FDA-approved peptide drug at a manufacturer's direct-pay price runs roughly $149 to $449 a month; a compounded peptide through a clinic runs roughly $185 to $300 per cycle or vial on the two clinic price pages we could actually quote; and a vial sold online "for research use only" can list near $105 for 10 mg. Those are not three prices for the same thing. They are three different transactions with different legal status, different quality assurance and different amounts of clinician involvement — and the cheapest is the one it is unlawful to sell for human use. Every figure below was read on the seller's own page on August 4, 2026 and attributed to the business that published it.

Why one number is impossible

"Peptide" is a chemistry word — a short chain of amino acids — not a category of medicine, as we set out in our primer. It covers FDA-approved GLP-1 drugs that have been through phase-3 trials, substances compounded by pharmacies with no approved product behind them, and molecules like retatrutide that are still in clinical development and sold anyway on hobbyist websites. Asking what peptide therapy costs is like asking what "a vehicle" costs.

So this article prices the three markets separately and does not argue whether any of these substances works. On links: we link sellers' own price pages so you can check the numbers, marked nofollow; we do not link research-peptide vendors at all, and where we name one we name it in plain text.

The price table

We have no information suggesting FDA has taken action against American Peptides specifically; we name it because a price without a named source is not a fact.

Market one: approved peptide drugs

The GLP-1 drugs are peptides. They are the only peptides in this article with large randomized efficacy trials behind them — STEP 1 randomized 1,961 adults — and, not coincidentally, the only ones with published, nationally uniform prices. Both manufacturers now sell direct to patients: that is the single most useful fact for anyone weighing a compounded offer against a branded one. Mechanics, eligibility and pharmacy routes are in our GLP-1 cost guide, the trade-offs in compounded versus branded.

Market two: compounded peptides through a clinic or telehealth service

What a prescriber may lawfully offer

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacist compounding for an individual patient may use a bulk drug substance only if it clears one of three gates, which FDA states as substances that "[c]omply with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph if one exists, and the USP chapter on pharmacy compounding"; that "[a]re components of FDA-approved drug products if an applicable USP or NF monograph does not exist"; or that "[a]ppear on FDA's list of bulk drug substances that can be used in compounding (the 503A bulks list) if such a monograph does not exist and the substance is not a component of an FDA-approved drug product" (FDA, page current as of May 14, 2026). Read FDA's wording closely and these are a ladder, not a menu: the bulks list only decides the cases the first two gates do not already cover. That list was created by a February 2019 final rule (84 FR 4696); additions require rulemaking, not a vote.

Separately, FDA maintains an interim "Category 2" list of substances that "may present significant safety risks." As of the version current April 22, 2026, that list includes ipamorelin acetate, with FDA's note that compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration," plus GHRP-2 and GHRP-6. BPC-157, TB-500 and CJC-1295 appear on the same page not in Category 2 but among substances nominated and then withdrawn. That is a meaningful distinction and it is routinely blurred in marketing.

The practical consequence is visible on the clinic menus themselves. The El Paso clinic in our table lists eighteen peptides, including tesamorelin alongside BPC-157, TB-500, MOTS-c, epithalon and CJC-1295/ipamorelin. Tesamorelin looks like the safe one, because it is the active ingredient of Egrifta, which FDA approved in 2010 — and that appearance is misleading. Egrifta is now a licensed biological product: FDA's Drugs@FDA record shows application BLA 022505, "Deemed To Be a BLA on March 23, 2020." And FDA's notice to compounders states that "biological products subject to licensure under section 351 of the PHS Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B." On that reading — ours, not a determination FDA has published about this clinic — being the active ingredient of an approved product does not bring tesamorelin inside 503A at all. One price page, several legal categories, and the most reassuring name on it is not the most settled.

What the July 2026 advisory vote did not change

FDA's Pharmacy Compounding Advisory Committee met July 23–24, 2026 and considered seven peptides, recommending six of them, BPC-157 among them by 8–6 with one abstention. Nothing changed legally on that date. FDA's own page states that "[a]dvisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so," and listing requires notice-and-comment rulemaking. We checked the Federal Register's API again on August 4, 2026: since January 1, 2026 the only document mentioning BPC-157 is the April 16, 2026 meeting notice itself. No proposed rule, no final rule, nothing. Our BPC-157 explainer covers the vote and the underlying evidence.

Published clinic pricing is scarce

We searched for clinics that publish peptide prices and found only two we could honestly quote from the clinic's own page. A third shows why: Revived Personalized Wellness in Houston has a page devoted to BPC-157 therapy whose only price block is headed "Sermorelin Injections Cost & Packages" — "$350 – $500" for a "30-Day Supply" — with no BPC-157 price anywhere on it (observed August 4, 2026; we do not link it). Most of what surfaces in a search for "peptide therapy cost" is not a clinic at all: it is affiliate-shaped content publishing ranges with no named seller behind them, plus one directory site whose footer concedes it is "an editorially curated reference directory." If a page gives you a range and cannot tell you whose price it is, it is not pricing information.

Telehealth is opaque in a different way. Ro and LifeMD publish membership fees clearly, and both state that medication cost is separate and variable. Strut Health's women's weight-loss page lists "Injectable Semaglutide — Auto Refill starting at $149" but nowhere on the listing says what period that covers, which is why it is not in our table. See how GLP-1 telehealth actually works and the three waves of FDA warning letters.

Market three: "research use only" vials

The cheapest peptides in America are sold by websites that say, in writing, that their products are not for people. FDA's position is that the disclaimer does not decide the question. In its March 31, 2026 warning letter to Gram Peptides, FDA wrote that "[d]espite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,'" the "evidence obtained from your website establishes that your products are intended to be drugs for human use." The site offered "'Retatrutide' (also referred to by your firm as 'GLP-1-R peptide') and 'Tirzepatide' … and 'Bacteriostatic Water for Injection'." FDA cited "sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)" — unapproved new drugs.

FDA wrote in the same terms the same day to Mile High Compounds LLC of Clifton, Colorado, over products sold as "GLP-1 SM," "GLP-2 TRZ," "GLP-3 RT" and "BAC Water" — so this is a position FDA is applying to the sector, not a one-off.

FDA's standing consumer page, current as of June 15, 2026, reports that as of May 31, 2026 it had received "990 reports of adverse events associated with compounded semaglutide" and "more than 730 reports of adverse events associated with compounded tirzepatide." Those are adverse-event reports, which establish neither causation nor a rate — but they are the only public tally that exists. The same page notes reports of dosing errors "some requiring hospitalization," and warns that salt forms such as "semaglutide sodium and semaglutide acetate, are different active ingredients."

What makes cheap peptides cheap

The $105 vial is not cheap because someone found efficiencies. It is cheap because the cost items have been removed — and the ladder starts higher up than most buyers realise. Even a lawfully compounded drug, FDA says, is "not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" — and a 503A pharmacy, unlike a 503B outsourcing facility, is not subject to current good manufacturing practice requirements at all (FDA compounding Q&A). The research vial then removes the prescriber and the pharmacy on top of that. A certificate of analysis posted by the seller is not a substitute for either.

Three worked examples

A year of Wegovy pens at the direct-pay price

Novo defines a month as one box of four weekly pens — 28 days. A 364-day year is therefore 13 boxes, not 12. A patient new to the offer pays $199 for the first two fills and $349 thereafter: (2 × $199) + (11 × $349) = $398 + $3,839 = $4,237 for 13 boxes covering 364 days. Budgeting 12 boxes instead gives $398 + (10 × $349) = $3,888 — but that only covers 336 days.

A year of Zepbound KwikPens, titrating up

Using Lilly's published self-pay ladder and the same 13-fill year, with one month at 2.5 mg, one at 5 mg and the rest at 7.5 mg or above: $299 + $399 + (11 × $449) = $299 + $399 + $4,939 = $5,637. Lilly's 45-day refill condition matters here: a gap longer than that, per the terms on its page, forfeits the offer price for that fill.

The per-milligram trap

A Wegovy 2.4 mg box contains four pens, so 9.6 mg of drug for $349 — $349 ÷ 9.6 mg = $36.35 per mg. The research-site retatrutide vial is $105 ÷ 10 mg = $10.50 per mg, about 3.5 times cheaper per milligram. That arithmetic is correct and the conclusion you might draw from it is wrong. They are different molecules with different potencies, so a milligram of one is not a therapeutic equivalent of a milligram of the other; one has an approved label, a lot number and a pharmacy behind it, the other has a disclaimer; and the cheaper one's own seller says it is not for human use. It is the single most misleading number in this market, and the one gray-market marketing leans on hardest.

What the price does and does not buy

HSA, FSA and insurance

Two IRS rules do most of the work here. First, deductible medicines must be prescribed: "You can include in medical expenses amounts you pay for prescribed medicines and drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual" (IRS Publication 502). Second, and more pointedly: "You can't include in medical expenses amounts you pay for illegal operations, treatments, or controlled substances whether rendered or prescribed by licensed or unlicensed practitioners." Publication 502 also allows weight-loss costs when the treatment is "for a specific disease diagnosed by a physician (such as obesity, hypertension, or heart disease)." Health FSAs key off the same definition: qualified medical expenses are "those specified in the plan that would generally qualify for the medical and dental expenses deduction" (IRS Publication 969). So a prescribed, lawfully dispensed peptide for a diagnosed condition is the case for reimbursement; a vial from a research site is not, and no plan administrator can make it one. This is general tax information, not tax advice.

Price questions for your prescriber

Our primer and BPC-157 explainer carry the evidence and safety questions. These five are the ones about money, and they are the ones clinic pages most often leave unanswered:

• Which specific substance are you prescribing, and is it an approved drug, a component of an approved drug, on the 503A bulks list, or none of those?
• Which pharmacy compounds it — a 503A pharmacy or a 503B outsourcing facility — and can I have the name?
• What is the total cost for a full course: medication, this visit, follow-up visits, labs, and supplies — as one number?
• What happens to the price when my dose goes up?
• What is the refill window, and what does a missed refill cost me?

Questions and answers

How much does peptide therapy cost per month in 2026?

It depends on the market. On the pages we read on August 4, 2026: an approved GLP-1 at a manufacturer's direct-pay price was $149 to $449 per month; at the two clinics we found that publish peptide prices, $185 to $270 per cycle at one and $250 per vial for BPC-157 at the other, in both cases before office visits or labs; a telehealth membership was $39 for the first month and $149 per month after, with medication billed separately. There is no single market price.

Is BPC-157 legal to prescribe now that FDA's advisers voted for it?

No. The July 23, 2026 vote was a non-binding recommendation. BPC-157 is not on the 503A bulks list, and as of August 4, 2026 the Federal Register contains no proposed or final rule to add it.

Why are research peptides so much cheaper?

Because the price excludes the prescriber, the pharmacist, the regulated manufacturing, the testing that would document identity and potency, and any recourse — and because selling them for human use is unlawful, so the seller carries none of the costs of doing it lawfully.

Can I use an HSA or FSA for peptide therapy?

For a prescribed drug treating a physician-diagnosed condition, that is the case IRS Publication 502 contemplates. For anything unlawful, Publication 502 is explicit that it cannot be included. Ask your plan administrator.

Sources

This article is general information about prices and law, not medical, legal or tax advice. Prices were observed on one day and change without notice. Discuss any medication decision with a licensed clinician who knows your health history.